Home › Prostate Cancer › California › Orange
Prostate Cancer clinical trials in Orange, CA
13 studies for Prostate Cancer are looking for participants at sites in and around Orange (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
RecruitingPhase 3
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
RecruitingPhase 3
- University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0006), Orange
Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
RecruitingPhase 1
- UCI Health Chao Family Comprehensive Cancer Center, Orange
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
RecruitingPhase 3
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
RecruitingPhase 3
- University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0040), Orange
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
RecruitingPhase 3
- University of California Irvine, Orange
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
RecruitingPhase 3
- Univ Cali Irvine ALS Neuromuscular, Orange
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
RecruitingPhase 3
- UC Irvine Health, Orange
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RecruitingPhase 2
- Chao Family Comprehensive Cancer Center, University of California Irvine, Orange
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
RecruitingPhase 3
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
RecruitingPhase 4
- St. Joseph Hospital, Orange
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer
RecruitingPhase 1/2
- UC Irvine Medical Center, Orange
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Orange
About Prostate Cancer
Prostate cancer is one of the most common types of cancer among American men. The risk goes up as men age. Learn about symptoms, tests, and treatment.
More about Prostate Cancer on MedlinePlus
Prostate Cancer trials in other cities
- New York City, NY101 studies
- Houston, TX73 studies
- Los Angeles, CA64 studies
- Boston, MA56 studies
- Seattle, WA45 studies
- St. Louis, MO45 studies
- Chicago, IL45 studies
- Baltimore, MD45 studies
- San Francisco, CA44 studies
- Philadelphia, PA41 studies
- Nashville, TN40 studies
- Washington, DC39 studies
Other studies in Orange
- Non-Small Cell Lung Cancer28 studies
- Metastatic Cancer21 studies
- Ovarian Cancer16 studies
- Colorectal Cancer16 studies
- Cancer (all types)15 studies
- Pancreatic Cancer15 studies
- Lung Cancer15 studies
- Liver Cancer (Hepatocellular Carcinoma)14 studies
- Melanoma14 studies
- Major Depressive Disorder13 studies
- Stomach Cancer13 studies
- Acute Myeloid Leukemia12 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.